4 completed, 1 not yet recruiting, 1 withdrawn. 2 Not applicable, 2 Phase 2, 1 Phase 1, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 2 | Completed 1, Not yet recruiting 1 |
| Phase 2 | 2 | Completed 2 |
| Phase 1 | 1 | Completed 1 |
| Phase 4 | 1 | Completed 1 |
Follow C. Difficile: new trials by email Literature Review of C. Difficile trials Research Report on C. Difficile
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clostridioides Difficile Controlled Human Infection Model encapsulated 10^4 CFU toxigenic. C. difficile spores, Vancomycin, Clindamycin - C. Difficile, C. Difficile Infection | Not applicable | Not yet recruiting | Leiden University Medical Center | 60 | 2025-03-01 | 2024-11-22 |
| Pre-emptive Prevention for Patients at High Risk for Hospital-onset Clostridioides Difficile Arm 1: Routine care, Arm 2: Preemptive C. difficile infection prevention bundle - C. Difficile | Not applicable | Completed | Brigham and Women's Hospital | 261 | 2022-07-25 | 2026-09-30 |
| Open-Label Extension of CP101 Trials Evaluating Oral Full-Spectrum Microbiota™ (CP101) in Subjects With Recurrence of Clostridium Difficile Infection CP101 - Clostridium Difficile Infection, Recurrent Clostridium Difficile Infection | Phase 2 | Completed | Finch Research and Development LLC. | 132 | 2018-05-01 | 2022-08-30 |
| Fecal Microbiota Transplantation to Treat Recurrent C. Difficile Associated Diarrhea Via Retention Enema or Oral Route Frozen Microbiota, Lyophilized Microbiota - C. Difficile | Phase 1 / Phase 2 | Completed | The University of Texas Health Science Center, Houston | 69 | 2015-03-17 | 2019-03-25 |
| Impact of Oral Antibiotic Treatment on C. Difficile Fidaxomicin, Metronidazole, Vancomycin - C. Difficile, Diarrhea | Phase 4 | Completed | Duke University | 33 | 2014-06-10 | 2019-10-02 |
| UARK 2009-99 A Non-interventional Observational Study of Infectious Complications in Cancer Patients Aspergillosis, Candidemia | Withdrawn | University of Arkansas | 2009-11-01 | 2015-10-27 |
Aspergillosis (1) · Candidemia (1) · Candidiasis (1) · Clostridium Infections (1) · Cross Infection (1) · Diabetes Insipidus, Neurogenic (1) · Diarrhea (1) · Enterocolitis (1) · Influenza, Human (1)
Infections (3) · Pathological Conditions, Signs and Symptoms (3) · Bacterial Infections and Mycoses (2) · Pathologic Processes (2) · Bacterial Infections (1) · Candidiasis, Invasive (1) · Diabetes Insipidus (1) · Digestive System Diseases (1) · Disease Attributes (1) · Endocrine System Diseases (1) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Fungemia (1) · Gastroenteritis (1) · Gastrointestinal Diseases (1)
Vancomycin (2) · Benchmarking (1) · Clindamycin (1) · Fidaxomicin (1) · Metronidazole (1)
Brigham and Women's Hospital (1) · Duke University (1) · Finch Research and Development LLC. (1) · Leiden University Medical Center (1) · The University of Texas Health Science Center, Houston (1) · University of Arkansas (1)
United States (5) · Canada (1) · Netherlands (1)
Daniel J Sexton, MD (1) · Meghan A Baker, MD, SCD (1) · Senu Apewokin, MD (1) · Zain Kassam, MD, MPH (1)